Clinical Trial Update: Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Irinotecan plus Cisplatin versus Pemetrexed plus Cisplatin as second-line therapy in advanced non-small cell lung cancer (Stage IIIB/IV)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Irinotecan (Irinotecan)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED